Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Fatigue 14Neoplasms 6Brain Neoplasms 5Prostatic Neoplasms 4Depression 4Sleep Wake Disorders 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Asthenia 2Recurrence 1Oligodendroglioma 1Neurotoxicity Syndromes 1Neurofibromatosis 1 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Meningioma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Ependymoma 1Cognitive Dysfunction 1Astrocytoma 1Anxiety Disorders 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × Methylphenidate × Clear all
NCT03525873 2026-04-15

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

M.D. Anderson Cancer Center

Phase 3 Active not recruiting
212 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡